Key result
Warfarin use for stroke prevention in atrial fibrillation was 59.4% in eligible patients, with age >80 years (OR 0.30) and language difficulties (OR 0.59) independently reducing prescription rates.
Why the study?
What demographic, clinical, and echocardiographic factors influence the decision to prescribe warfarin in patients with chronic atrial fibrillation?
Observational (n=1,027)
What demographic, clinical, and echocardiographic factors influence the decision to prescribe warfarin in patients with chronic atrial fibrillation?
Despite established benefits, warfarin remains underused in atrial fibrillation, with older age, language barriers, and physician-related factors contributing to reluctance to treat.
No takes yet. Share an insight, caveat, or question.
Barriers to warfarin in eligible AF patients highlight potential inequities; leaves open whether targeted interventions improve prescription rates.
Cohen et al. (2000) conducted an observational in Chronic or persistent atrial fibrillation (n=1,027). Warfarin was evaluated on Warfarin use on discharge in the main study group. Warfarin use for stroke prevention in atrial fibrillation was 59.4% in eligible patients, with age >80 years (OR 0.30) and language difficulties (OR 0.59) independently reducing prescription rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: